Last updated: May 28, 2026
WELLBUTRIN XL is a branded, extended-release bupropion hydrochloride product. In the US, supply is primarily controlled by the product’s listed FDA manufacturing sites (Orange Book/label) and by upstream API and excipient supply used for extended-release tablet manufacture. A supplier map for WELLBUTRIN XL depends on the specific NDA-holder and the currently listed finished-dose manufacturers and label claimants for the latest marketed strengths (typically 150 mg and 300 mg).
Because no jurisdiction, strength, and current label/NDC set are specified, a complete, accurate supplier list cannot be produced from the information provided.
What companies are suppliers for WELLBUTRIN XL (bupropion XL) finished-dose tablets in the US?
Answer: Finished-dose suppliers for WELLBUTRIN XL are the companies listed on the US prescribing label and corresponding FDA Orange Book entry for the specific NDC(s) marketed at that time.
Where do you find WELLBUTRIN XL manufacturing sites
- FDA Orange Book “Manufactured for” / applicant and patent listing records for the NDA.
- Current prescribing information label section listing manufacturer(s).
- NDC-specific labelers tied to marketed lots.
Why suppliers vary by strength and NDC
WELLBUTRIN XL is marketed in multiple strengths and NDC configurations, and manufacturers can differ across NDCs even when the active ingredient is the same.
Who supplies the bupropion API for WELLBUTRIN XL?
Answer: The API supplier is the company or site(s) supplying bupropion hydrochloride used by the finished-dose manufacturer for the NDA.
Upstream API supply is controlled by
- Controlled manufacturing agreements between the NDA holder and the contract manufacturer.
- Site qualifications for API suppliers used for ANDA-beating changes or internal batch continuity.
- Excipient and processing constraints specific to extended-release matrix tablets.
Which excipient and extended-release tablet suppliers support WELLBUTRIN XL?
Answer: Extended-release tablets rely on excipients and controlled-release matrix components supplied and qualified to specific formulation specs.
Key supplier categories in extended-release tablet manufacturing
- Hydrophilic or polymeric matrix components
- Film coatings and colorant suppliers
- Glidants, binders, and compression aids
- Dedicated packaging line suppliers for unit-dose integrity
What is the Orange Book status of WELLBUTRIN XL, and how does it affect supply?
Answer: The Orange Book status indicates patent and exclusivity timing for the NDA, which affects generic competition and can indirectly affect supplier utilization and volume planning.
How Orange Book timing influences sourcing
- If branded exclusivity is intact, supply is mostly exercised by the NDA holder and its chosen manufacturers.
- Patent challenges affect demand expectations and can lead to additional supply redundancy or capacity lock-in.
How do contract manufacturing and label changes change WELLBUTRIN XL suppliers over time?
Answer: WELLBUTRIN XL suppliers can change when the NDA holder qualifies new manufacturing sites, updates labeler/NDC mapping, or transfers production.
Common drivers
- Capacity balancing across tablets and strengths
- Tech transfer to meet surge demand
- Cost-optimization or site rationalization
What generic entry risks exist for WELLBUTRIN XL, and do they change supplier strategy?
Answer: Generic entry risks exist when ANDAs are permitted to reference the NDA and launch with approved labeling. Supplier strategy can change around anticipated competition, but an accurate risk assessment requires the active patent and exclusivity landscape for the specific WELLBUTRIN XL strengths.
What litigation or settlement agreements affect WELLBUTRIN XL supply or manufacturing?
Answer: Patent litigation and settlements can affect when and how generics enter, which can alter branded procurement and production planning. Determining the impact requires the specific patent estate and any settlement terms tied to the NDA.
How to build a defensible WELLBUTRIN XL supplier list (audit-ready)
Answer: The only defensible supplier list for WELLBUTRIN XL is built from the current FDA-labeled manufacturing sites and the NDA’s applicant/manufacturer records for the specific NDC(s).
Deliverables for an audit-ready supplier map
- Finished-dose manufacturers by strength and NDC
- NDA applicant and label claimants
- Manufacturing sites tied to batch release statements (label and FDA records)
- Upstream API supplier chain only where explicitly disclosed in regulatory filings or validated commercial intelligence
Key Takeaways
- WELLBUTRIN XL supplier identification must be grounded in FDA Orange Book and current prescribing label manufacturing-site listings for the exact strength and NDC(s).
- Upstream API and excipient suppliers are not reliably derivable without those NDA-linked records for current marketed configurations.
- Supplier lists for extended-release tablets can vary by strength and labeler/NDC mapping due to contract manufacturing and site qualification changes.
FAQs
- How do I identify the current manufacturer for WELLBUTRIN XL 150 mg versus 300 mg?
- Does WELLBUTRIN XL supplier information differ by NDC labeler?
- Are bupropion HCl XL API suppliers disclosed in FDA or label documents?
- What Orange Book fields are used to trace WELLBUTRIN XL NDA-linked manufacturing?
- How does an FDA manufacturing site change show up for WELLBUTRIN XL supply mapping?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Orange Book database). https://www.accessdata.fda.gov/scripts/cder/daf/
- FDA. Drugs@FDA. (NDA and labeling information). https://www.accessdata.fda.gov/scripts/cder/daf/
